- Home
- IPHA vs PMN Comparison
IPHA vs PMN Comparison
Compare IPHA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | PMN |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | France | Canada |
| Employees | 174 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.4M | 115.5M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | IPHA | PMN |
|---|---|---|
| Price | $1.64 | $11.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.75 | ★ $42.67 |
| AVG Volume (30 Days) | 24.8K | ★ 34.1K |
| Earning Date | 03-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $181.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $0.29 |
| 52 Week High | $2.63 | $27.40 |
Technical Indicators
Market Signals| Indicator | IPHA | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 62.58 | 35.71 |
| Support Level | $1.60 | $10.57 |
| Resistance Level | $1.83 | $19.85 |
| Average True Range (ATR) | 0.08 | 1.36 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 84.03 | 20.68 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.